PeptideStack
5.2kquestions
20kanswers
220users

How does semaglutide at 2.4 mg weekly compare on cost per milligram across routes?

Asked 9 May 2024Modified 2.0 years agoViewed 36k times
25

The case in front of me: semaglutide · 2.4 mg.

Please show the division. I want to check my own against yours.

I would like the general form as well as the specific number, so I can apply it again.

How many significant figures are actually justified here?

cost-analysis
cost-analysis

Cost arithmetic done honestly: cost per milligram after dead-space loss, list versus net price, comparing a multi-dose vial to a fixed-dose pen,…

260 questions
vendor-comparison
vendor-comparison

Side-by-side comparison of suppliers on measurable axes - independently confirmed purity and content, lead time, cold-chain handling,…

388 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
shareeditfollowflag
SS
askedswab_stopper8.8k139 May 2024
6Same question before my first order, and the small-order-then-test route worked. – bac_or_bust 3 months ago
7Do you have a certificate in front of you, or are you asking before requesting one? – Dr_Colm_Fitzhenry 5 months ago
add a comment

5 Answers

Accepted answer first, then by votes
77

Accepted answer

2.4 mg a week is 125 mg a year and 10.4 mg in an average month — put every route on that denominator before comparing anything. Cost per milligram is the only figure that survives the comparison, because the presentations differ: a licensed pen prices a dose, a compounding pharmacy prices a vial, and a research supplier prices a mass. Divide each one's twelve-month cost by 125 mg and the three become the same number in the same unit. Then add what the cheapest route does not include — independent purity and content testing, the vials you discard, and the postage — because a route that needs testing to be trustworthy has that testing in its cost per milligram whether you account for it or not.

Start by listing every cost in the chain, since carriage, testing and wastage frequently exceed the difference in headline price.

Worked example. Supplier A: £60 for a 10 mg vial, content 96 per cent, so 9.6 mg for £60, or £6.25/mg before carriage. Supplier B: £52 for the same nominal vial, content 88 per cent, so 8.8 mg for £52, or £5.91/mg. B still wins here, but the gap has narrowed from thirteen per cent on the label to five per cent in reality.

Certificate red flags and what each implies

ObservationImplicationHow to check
Lot number not on the vialCertificate cannot be tied to your materialPhotograph vial and certificate together
No method sectionThe number is not reproducibleRequest column, gradient, wavelength
Purity to two decimals, no chromatogramFalse precisionRequest the trace
Test date before manufacture dateCertificate belongs to a different lotCompare dates
Identical figures across lotsOne certificate reusedCompare two lots side by side
“Sterile filtered” with no sterility testProcess claim substituted for a resultAsk for the sterility report

The underlying point is that dead-space loss is small with fixed-needle insulin syringes — a few microlitres per draw — and substantial with detachable-needle luer syringes at 35 to 100 microlitres. Across twenty draws that is up to two millilitres of solution.

Syringe dead-space volumes are published per design, with fixed-needle insulin syringes under 5 microlitres and conventional luer designs at 35 microlitres or more.

Include carriage and testing as per-milligram terms. They dominate small orders.

shareimprove this answerflag
DV
answered · acceptedDr_Ilse_Vandenberg113k24810 Jul 2024
7I have kept every invoice and declaration, which I gather is the useful habit. – seven_day_half 7 months ago
8The cost-per-milligram-of-measured-content correction reversed my own spreadsheet. – ilaria_bertone 9 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
93

Concretely, this is a spreadsheet question and doing it properly changes conclusions more often than people expect.

Carriage amortises across the order. Twenty-five pounds of carriage on one vial is £2.50/mg on a 10 mg vial; on ten vials it is £0.25/mg. That single term explains most of the case for larger, less frequent orders.

The full calculation: (unit price + carriage share + testing share) ÷ (nominal mg × measured content fraction × (1 − dead-space and wastage fraction)). Every term after the first is routinely omitted.

A spreadsheet built on label claim rather than measured content is precise about the wrong number.

Divide by measured content, not by label claim. That is the whole correction.

shareimprove this answerflag
WO
answeredw_okoye43k1372 Aug 2024
61

More usefully, wastage from expired reconstituted vials is a real line item and nobody includes it.

Change one number and it reverses: if B assays at 82 per cent, that is 8.2 mg for £52, or £6.34/mg, and the cheaper vial is now the more expensive peptide.

Wastage from a reconstituted vial discarded at the end of its in-use period is a genuine cost, and it is a function of the diluent volume chosen at reconstitution rather than of anything the supplier did.

Published content assay results across the independent services show nominal and measured content differing by one to ten per cent, which is the term that makes label-price comparisons unreliable.

Larger orders reduce cost per milligram and increase exposure to a single lot, which is a real trade rather than a free win.

Larger orders are cheaper per milligram and concentrate lot risk. Price both.

shareimprove this answerflag
BB
answeredbac_or_bust33k13713 Aug 2024
36

The short version: unit price, carriage, testing, dead-space loss and wastage. The first is the one everybody compares and rarely the one that decides it.

Cost per milligram is the wrong metric entirely if you are optimising for confidence rather than price, and it is worth saying which one you are doing before you build the spreadsheet.

Independent testing prices at the services this community uses are published and are stable enough to model.

Decide whether you are optimising cost or confidence before you build the model.

shareimprove this answerflag
PH
answeredpetra_hovland35k3822 Jul 2024
30

The part that matters: testing cost per milligram falls sharply with order size, which is the main argument against very small repeat orders.

Independent testing costs roughly the price of one to two vials at the services this community uses. On a two-vial order that is a fifty to a hundred per cent surcharge; on a twenty-vial order it is five per cent.

Carriage on international consignments scales sub-linearly with weight, which is the quantitative basis for order consolidation.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Fixed-needle syringes save more peptide than most price differences do.

shareimprove this answerflag
SB
answereds_bhattacharya31k3818 May 2024

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.